15 PRRS control is hampered by the inadequacies of existing vaccines to combat the extreme 16 diversity of circulating viruses. Since immune clearance of PRRSV infection may not be 17 dependent on the development of neutralising antibodies and the identification of broadly-18 neutralising antibody epitopes have proven elusive we hypothesised that conserved T cell 19 antigens represent potential candidates for development of a novel PRRS vaccine. Previously 20 we had identified the M and NSP5 proteins as well-conserved targets of polyfunctional CD8 21 and CD4 T cells. To assess their vaccine potential, peptides representing M and NSP5 were 22 encapsulated in hydrophobically-modified chitosan particles adjuvanted by incorporation of a 23 synthetic multi-TLR2/TLR7 agonist and coated with a model B cell PRRSV antigen. For 24 comparison, empty particles and adjuvanted particles encapsulating inactivated PRRSV-1 25 focus on enhancing the cross-presentation M/NSP5 to CD8 T cells. 35
were prepared. Vaccination with the particulate formulations induced antigen-specific 26 antibody responses, which were most pronounced following booster immunisation. M and 27 NSP5-specific CD4, but not CD8, T cell IFN-γ reactivity was measurable following the 28 booster immunisation in a proportion of animals vaccinated with peptide-loaded particles. 29
Upon challenge, CD4 and CD8 T cell reactivity was detected in all groups, with the greatest 30 responses being detected in the peptide vaccinated group but with limited evidence of an 31 enhanced control of viraemia. Analysis of the lungs during the resolution of infection showed 32 significant M/NSP5 specific IFN-γ responses from CD8 rather than CD4 T cells. Vaccine 33 primed CD8 T cell responses may therefore be required for protection and future work should 34
Introduction 38
Porcine reproductive and respiratory syndrome (PRRS) is one of the most important pig 39 diseases worldwide. The causative PRRS virus (PRRSV) is rapidly evolving and there is an 40 urgent need for the development of safer and more efficacious vaccines to improve PRRS 41 control. Efforts to develop improved vaccines have focused primarily on the structural 42 envelope glycoproteins but these have met with limited success and thus alternative 43 approaches are required (Murtaugh and Genzow, 2011; Renukaradhya et al., 2015) . While the 44 immunological mechanisms underlying protection against PRRSV remain to be fully defined, 45 there is evidence to suggest that cell-mediated immune responses play an important role 46 (Murtaugh and Genzow, 2011; Zuckermann et al., 2007) . Indeed, T cells are crucial to the 47 control of many viruses through cytolysis of infected cells and cytokine secretion. Since 48 clearance of PRRSV infection may not be dependent on neutralising antibodies, we 49 hypothesised that conserved PRRSV T cell antigens should be considered as an integral 50 component of any next-generation PRRSV vaccine. Through proteome-wide peptide library 51 screening, we identified both the structural matrix (M) protein and the non-structural protein 52 5 (NSP5) from PRRSV genotype 1 (PRRSV-1) as well conserved targets of T cell immunity 53 (Mokhtar et al., 2016) , which warranted further evaluation of their vaccine potential. 54
Amongst the range of vaccine delivery systems being developed to induce T cell mediated 55 immunity to defined antigens, one strategy which possesses a number of desirable features is 56 the use of nano-or micro-particles to deliver vaccine antigen to dendritic cells (DCs). Both 57 antigens in protein or plasmid DNA form can be encapsulated inside or coated to the surface 58 of biodegradable particles which allows for sustained release after administration, increasing 59 the bioavailability and decreasing the degradation (Bivas-Benita et al., 2004; Shen et al., 60 2006) . The efficient internalisation of the particle is a distinct advantage and if taken up by 61 dendritic cell (DC) allows the cargo of antigen to be potentially processed via the MHC class 62 I or II presentation pathways (Hirosue et al., 2010) . In addition, particles can carry molecular 63 adjuvants thus delivering the appropriate stimulatory signals together with the antigen to 64 individual DC. Particulate vaccines have been evaluated in the context of PRRSV, with killed 65 PRRSV encapsulated inside poly(lactic, glycolic acid) (PLGA) particles and administered 66 intranasally to pigs resulting in enhanced antibody and T cell responses that translated to 67 cross-protective immunity (Binjawadagi et al., 2014a; Binjawadagi et al., 2014b; Dwivedi et 68 al., 2013) . Amongst the available polymers used to produce particles, chitosan has a number 69 of attractive features for vaccine delivery. Chitosan and its derivatives are abundantly 70 expressed biological polysaccharides which readily form particles (Jayakumar et al., 2010) . 71
Chitosan may offer an inherent adjuvant effect through binding the innate immune sensor, 72
Toll-like receptor 4 (TLR4), and has been shown to bind specifically to mannose receptors 73 expressed on DCs (Villiers et al., 2009 ). This study therefore evaluated the immunogenicity 74 of chitosan particles loaded with M and NSP5 antigens in comparison to inactivated PRRSV-75 1. Since it has been shown that targeting multiple TLRs augments vaccine immunogenicity 76 and efficacy (Kasturi et al., 2011; Querec et al., 2006) , particles were adjuvanted by 77 incorporation of the synthetic multi-TLR2/TLR7 agonist Adilipoline™. 78
Materials and methods 79

Ethics statement 80
All work was approved by the APHA Ethics Committee and conducted in accordance with 81 the UK Animals (Scientific Procedures) Act 1986 under Project Licence numbers PPL 82 70/7057 and 70/7209. 83
PRRS viruses, peptides and proteins 84
The PRRSV-1 subtype 1 strains Olot/91 and 215-06 were propagated and titrated in MARC-85 145 cells and porcine alveolar macrophages, respectively ( peptides; and Empty-P -sterile deionised water. 15% PVA was added to each preparation and 111 homogenised for 1 minute followed by probe sonication for 2 minutes (amplitude 17 112 microns). The mixtures were then added drop-wise to 1% PVA whilst homogenising for 4 113 minutes. Following removal of solvent by evaporation, the following were adsorbed onto the 114 surface of the particles by adding drop-wise whilst on a magnetic stirring block: Virus-P -115 50µg Adilipoline/dose; Peptide-P -50µg Adilipoline and 200µg EM4 protein/dose and 116 Empty-P were left untreated. All vaccine formulations were diluted to 4ml per dose with 117 sterile water. The surface charge of particles was measured using a Zeta Sizer 3000 (Malvern 118 Instruments, Malvern, UK) and particle morphology and size assessed using scanning 119 electron microscopy (Walters et al., 2015) . To assess loading and coating efficiencies aliquots 120 of each formulation were centrifuged at 14000 rpm for 5 min and supernatants were 121 harvested and stored at -80°C until analysed. ELISA and biochemical assay analyses of 122 particle-free supernatants were conducted to determine the efficiency of virus (ELISA) or 123 peptide (fluorometric o-phthalaldehyde assay) encapsulation and coating with EM4 protein 124 (ELISA). Absorption of EM4 to particle surfaces was additionally assessed by flow 125 cytometric staining of particles (Walters et al., 2015) . Further details of these assays are 126 provided in Supplementary Materials. consisted of empty chitosan particles (Empty-P). Scanning electron microscopy showed 220 particles with a spherical morphology and a typical diameter less than 5µm ( Figure 1B) . The 221
Virus-P tended to be larger and to collapse more easily, possibly due to the volume of antigen 222 encapsulated. Zeta potential measurements showed the Virus-P to be negatively charged 223
whereas the Peptide-P and Empty-P were positively charged, which most likely reflected 224 their differing composition ( Figure 1C) . 225
To assess the efficiency of virus or peptide encapsulation and coating with EM4 protein, 226 antigen was quantified in particle-free supernatants (Supplementary Figure S1 ). Inactivated 227 PRRSV Olot/91 and EM4 were assessed using antigen-capture ELISAs and the encapsulation 228 efficiencies were calculated to be over 99% efficient. The adsorption of EM4 protein onto the 229 surface of ~80% of Peptide-P was additionally demonstrated by flow cytometry 230 (Supplementary Figure S2) . Given the high efficiency of EM4-coating, a fluorometric 231 biochemical assay was conducted to assess the encapsulation of M and NSP5 peptides which 232
were be estimated to be at >98% efficient (Supplementary Figure S1 ). Assessment of 233
Adilipoline incorporation was not undertaken as it was not readily amenable to assessment by 234 ELISA or other means e.g. HPLC. 235
The particles were screened in vitro to assess the cytokine response profiles of blood Virus-P induced a statistically significant monocyte IL-10 response, suggestive that this was 247 virus-rather than Adilipoline-specific. Whilst not detected in monocyte cultures, statistically 248 significant IL-12 and type I IFN responses were detected in DC cultures following 249 stimulation with both Virus-and Peptide-P, irrespective of washing, suggesting that particle-250 associated Adilipoline was inducing these responses. 251
Assessment of immune responses and protection following experimental vaccination in 252 pigs 253
Groups of pigs (n=6) were vaccinated twice with each of the particulate formulations (Virus-254 P, Peptide-P and Empty-P) with a three week interval between prime and booster 255 inoculations. After a further three weeks, all animals were challenged with a UK field strain 256 of PRRSV-1 (215-06) and assessed for protection. Over the duration of the experiment, the 257 induction of antigen-specific antibody and T cell responses were monitored and protection 258 assessed by measuring viraemia by quantitative RT-PCR. 259
Assessment of PRRSV-specific antibody responses using a commercial N protein-based 260 ELISA showed that after the booster immunization, significant levels of specific antibodies 261 were detected in the Virus-P immunised group ( Figure 3A) . These responses were rapidly 262 boosted by challenge infection and were significantly greater than the Peptide-and Empty-P 263 groups on days 7 and 14 post-challenge). Significant EM4-specific antibody responses were 264 detected in the Peptide-P immunised group from day 28 (7 days post booster immunisation) 265 which remained elevated for the duration of the study ( Figure 3B The BALF cellularity and composition was determined, and T cell responses measured 289 following stimulation with PRRSV or a pool of M/NSP5 peptides ( Figure 6 ). For technical 290 reasons it was not possible to collect BALF from all animals. The results showed that for all 291 animals irrespective of vaccine group there was a significantly greater number of CD8 292 compared to CD4 T cells within the lavage fluid. Assessment of antigen-specific responses 293
showed that again for all animals there was a statistically significantly higher frequency of 294 PRRSV and M/NSP5 specific CD8 T cells compared to CD4. The frequency of antigen-295 specific CD8 T cells in BALF was much higher than had been detected in blood ( Figure 5) . 296
Discussion 297
The results of this study have shown that hydrophobically-modified chitosan may be used to 298 efficiently generate particulate formulations of either whole PRRSV or defined PRRSV 299 antigens. Further enhancement of the immunostimulatory nature of these particles by co-300 formulation with the multi-PRR ligand Adilipoline was demonstrated in vitro. However, 301 despite the encouraging in vitro data, vaccination with these formulations induced antibody 302 responses but failed to induce strong antigen-specific T cell responses, which are believed to 303 be required for the effective control of PRRSV infection in the absence of neutralising 304 antibodies (Morgan et al., 2013; Murtaugh and Genzow, 2011; Weesendorp et al., 2013; 305 Zuckermann et al., 2007) . It is worthy to note that the Peptide-P formulation appeared to 306 prime at least in half the animals CD4 as opposed to CD8 T cell responses. The data from the 307 lung lavages following the resolution of the PRRSV infection was striking and would further 308 suggest that it was a lack of CD8 T cell response that may underlie the poor vaccine efficacy 309 observed. The vaccine formulations did result in cross-presentation of antigen to memory 310
CD8 T cells in vitro, albeit with a lower efficiency than to CD4 T cells (data not shown). 311
Several factors may underlie the poor T cell immunogenicity of these particles including the 312 choice of polymer, the size of the particles and the quantity of antigen/adjuvant loaded. 313
Chitosan was selected as the polymer core of the particulate vaccines due to its inherent 314 immunostimulatory properties (Highton et al., 2015; Zaharoff et al., 2007; Zhu et al., 2007) , 315 which is thought to be mediated through engagement of TLR4 and mannose receptors on 316 antigen-presenting cells (Villiers et al., 2009 ). Rather unexpectedly, the results of the in vitro 317 evaluation of our chitosan particles showed that non-adjuvanted particles failed to induce 318 cytokine responses from porcine DCs and elicited only an IL-8 response from monocytes. 319
The formulated particles in the present study were in the low micron range, which is at the 320 upper range of optimal particle size for phagocytosis by DCs and macrophages (He et al., 321 2010; Thiele et al., 2001) . Whilst outside the scope of the present study, formulation 322 conditions may be manipulated to create antigen encapsulated chitosan particles with discrete 323 nominal sizes. A recent study of chitosan particles of 300nm, 1µm, and 3µm parameters 324 showed that 1μm particles were optimal for phagocytosis by macrophages but uptake by DC 325 was independent of particle size (Koppolu and Zaharoff, 2013) . Interestingly the three 326 particle sizes induced discrete DC cytokine response profiles and the 3μm particles were best 327 at stimulating antigen-presentation and CD4 T cell responses; which was attributed to 328 augmented antigen encapsulation efficiency (Koppolu and Zaharoff, 2013) . In the present 329 study, we indirectly assessed the formulated antigen cargo by quantifying antigen that 330 remained in supernatants following formulation. Whilst these analyses suggested very high 331 (>90%) encapsulation and coating efficiencies, in line with previous studies (Koppolu and Another factor which needs to be considered in the future is the route of inoculation. In 345 contrast to peripheral blood where both CD4 and CD8 T cell responses were detected, the 346 virus and M/NSP5 specific response in the lung were almost exclusively from CD8 T cells 347 and this was accompanied by a greater infiltrate of these cells compared to CD4 T cells. 348
These data support earlier observations (Samsom et al., 2000) and suggest that the CD8 T cell 
